Similar Search Results

An exploratory study of FDA new drug review times, Prescription Drug User Fee Acts, and R&D spending

Vernon, John A.; Golec, Joseph; Lutter, Randall W.; … - In: The quarterly review of economics and finance : journal … 49 (2009) 4, pp. 1260-1274

Persistent link: https://www.econbiz.de/10003903758

Black Box Warnings and drug safety : examining the determinants and timing of FDA warning labels

Begosh, Allan; Goldsmith, John; Hass, Ed; Lutter, Randall W. - 2006

Persistent link: https://www.econbiz.de/10003407440

Black Box Warnings and Drug Safety : Examining the Determinants and Timing of FDA Warning Labels

Begosh, Allan - 2006

Comparing the safety of prescription drugs over time is difficult due to the paucity of reliable quantitative measures of drug safety. Both the academic literature and popular press have focused on drug withdrawals as a proxy for breakdowns in the drug safety system. This metric, however, is...

Persistent link: https://www.econbiz.de/10012465856

The signaling effects of incremental information : evidence from stacked US Food and Drug Administration designations

Miller, Kathleen L.; Nardinelli, Clark; Pink, George H.; … - In: The quarterly review of economics and finance : journal … 67 (2018), pp. 219-226

Persistent link: https://www.econbiz.de/10012034461

The signaling effects of the US food and drug administration fast-track designation

Miller, Kathleen L.; Nardinelli, Clark; Pink, George H.; … - In: Managerial and decision economics : MDE ; the … 38 (2017) 4, pp. 581-594

Persistent link: https://www.econbiz.de/10011738902

Willingness to pay to standardize patient medication information

Dealy, Bern Caudill; Kearsley, Aaron; Wolff, Carolyn; … - In: Applied economics 53 (2021) 9, pp. 1112-1126

Persistent link: https://www.econbiz.de/10012425452